HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Business Round-Up: BioGaia Held Back By COVID, Nutrinovate Acquires Vitamin Sprays, Labomar Goes Public

Executive Summary

Latest EU business news: Sweden's BioGaia warns sales to slump due to COVID-19; Nutrinovate acquires vitamin sprays firm A to K; and Italy's Labomar prepares for M&A following IPO.

You may also be interested in...



EU Probiotics News: Strong Year For Probi, BioGaia Struggles, Kerry Targets Biosearch Deal

Latest European Probiotics News: Probi and BioGaia post earnings, with differing results, while Kerry seeks to expand with Spain's Biosearch.

BioGaia Gets Private Equity Backing To Fuel Growth

Probiotics specialist BioGaia will draw on the experience of its new private equity investor EQT as it looks to expand through acquisitions and increased digitization.

Germany's EVP Enters Spain's Supplements Market With Korott

German private-label specialist EVP Group is poised to enter the Spanish market with the acquisition of local supplements and cosmetics player Korott.

Topics

UsernamePublicRestriction

Register

RS150567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel